Position in IPHA
as of Jun 30, 2026
· filed Sep 2, 2026
Position Value
$22,891
-$15,790 QoQ
Shares Held
12,441
-37.9% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#5
of 10 holders
Holding Since
Mar 2021
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in IPHA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CITADEL ADVISORS LLC holds $6,150,763,744 across 435 Biotechnology names. IPHA ranks #407 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ONC |
BeOne Medicines Ltd.
|
1,425,517 | $406,229,578 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
3,760,028 | $280,046,885 | |
| 3 | INSM |
INSMED Inc
|
2,556,973 | $272,624,460 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
507,233 | $272,358,759 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
510,430 | $253,545,893 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,006,676 | $242,578,715 | |
| 7 | MANE |
Veradermics, Inc
|
1,877,775 | $230,853,658 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
5,576,261 | $197,343,876 |
All Filings in IPHA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22,891 | 12,441 | Shares | Defined | 2026-09-02 | |
| 2025-09-30 | $38,681 | 20,042 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $48,309 | 26,617 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $43,195 | 24,267 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $21,809 | 11,853 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $48,701 | 21,267 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $45,642 | 23,527 | Shares | Defined | 2024-08-14 | |
| 2023-06-30 | $40,839 | 13,281 | Shares | Defined | 2023-08-14 | |
| 2021-03-31 | $108,827 | 25,250 | Shares | Defined | 2021-05-21 | |
| No filing history on record for this holder in this stock. | ||||||